[1]彭 冉,李慕梓,刘宇洲,等.微球联合碘化油TACE治疗肝细胞癌的疗效和安全性[J].介入放射学杂志,2023,32(03):265-271.
 PENG Ran,LI Muzi,LIU Yuzhou,et al.The efficacy and safety of TACE by using microspheres plus iodized oil for hepatocellular carcinoma[J].journal interventional radiology,2023,32(03):265-271.
点击复制

微球联合碘化油TACE治疗肝细胞癌的疗效和安全性()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
32
期数:
2023年03
页码:
265-271
栏目:
临床研究
出版日期:
2023-03-31

文章信息/Info

Title:
The efficacy and safety of TACE by using microspheres plus iodized oil for hepatocellular carcinoma
作者:
彭 冉 李慕梓 刘宇洲 谢 勇 向 华
Author(s):
PENG Ran LI Muzi LIU Yuzhou XIE Yong XIANG Hua.
Department of Interventional Vascular Surgery, Hunan Provincial People’s Hospital, First Affiliated Hospital of Hunan Normal University, Changsha, Hunan Province 410005, China
关键词:
【关键词】 肝细胞癌 微球 碘化油 栓塞化疗 Meta分析
文献标志码:
A
摘要:
【摘要】 目的 比较微球联合碘化油与单纯碘化油经肝动脉化疗栓塞术(TACE)治疗肝细胞癌的有效性和安全性。方法 检索建库到2022年1月Pubmed、Web of Science、Cochrane Library、Embase、Clinical trials、中国知网、维普数据库、万方数据库中比较微球联合碘化油与单纯碘化油经动脉化疗栓塞治疗肝细胞癌的所有文献,语种不限。采用Cochrane协作网站的RevMan5.1软件进行数据分析。结果 最终入选11篇文献,共778例患者。 分析显示,接受微球联合碘化油TACE治疗的患者客观缓解率(OR=2.61,95% CI:1.84~3.71,P<0.01)、疾病控制率(OR=3.73, 95%CI:2.30~6.07,P<0.01)、术后6个月生存率(OR=1.82,95% CI:1.09~3.04,P=0.02)、术后1年生存率(OR=2.94,95% CI:1.91~4.51,P<0.01)均高于接受单纯碘化油TACE治疗的患者。两组术后2年生存率、发热发生率、恶性呕吐发生率和肝区疼痛发生率差异均无统计学意义(均P>0.05)。 结论 微球联合碘化油TACE治疗肝细胞癌在提高客观缓解率、疾病控制率、术后6个月、1年生存率方面具有显著优势,但是,其安全性及术后2年生存率尚待进一步观察。

参考文献/References:

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality world wide for 36 cancers in 185 countries[J]. CA Cancer Clin, 2018, 68: 394- 424.
[2] Ferlay J,Colombet M,Soerjomataram I,et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sourcers and methods[J]. Int J Cancer, 2019, 144: 1941- 1953.
[3] Ferenci P,Fried M,Labrecque D,et al. Hepatocellular carcinoma (HCC): a global perspective[J]. J Clin Gastroenterol, 2010, 44: 239- 245.
[4] Malkowski P,Pacholczyk M,Lagiewska B,et al. Hepatocellular carcinoma- epidemiology and treatment[J]. Przegl Epidemiol, 2006, 60: 731-740.
[5] Tancredi T, Mccuskey PA, Kan Z, et al. Changes in rat liver microcirculation after experimental hepatic arterial embolization: comparison of different embolic agents[J]. Radiology, 1999, 211: 177- 181.
[6] 中国医师协会介入医师分会临床诊疗指南专委会, cn112137- 2021. 中国肝细胞癌经动脉化疗栓塞(TACE)治 疗 临 床 实 践 指南(2021 年 版)[J]. 中华医学杂志 , 2021, 101: 1848- 1862.
[7] 张 训,徐燕能,张向琼,等. CalliSpheres载药微球联合碘化油治疗大肝癌14例[J]. 介入放射学杂志, 2020, 29:39- 44.
[8] 罗剑钧,颜志平,王建华,等. 微球+碘化油联合栓塞与碘化油单独栓塞治疗肝癌的比较研究[J]. 中国医学计算机成像杂志, 2008, 14:154- 159.
[9] Yamasaki T, Hamabe S, Saeki I, et al. A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial[J]. J Gastroenterol, 2011,46:359- 366.
[10] 翁志成,杨维竹. 联合微球和碘化油化疗栓塞治疗巨块型肝细胞癌的疗效评价[J]. 中华放射学杂志, 2011, 45:274- 278.
[11] 陈红栓,白旭明,程 龙,等. 栓塞微球联合碘化油化疗栓塞治疗肝癌的临床研究[J]. 实用医学影像杂志, 2012, 13:266- 269.
[12] 赵玉山.葡聚糖微球联合碘化油介入治疗原发性肝癌的临床应用研究[D]. 太原:山西医科大学, 2012.
[13] 徐文杰,曹 刚,张根山,等. 聚乙烯醇栓塞微球可载药微球介入治疗中晚期肝癌的临床疗效及安全性观察[J].实用癌症杂志, 2017, 32:1999- 2001.
[14] 游建雄,王精兵,艾松涛,等. 微球联合碘油栓塞治疗肝癌的近期疗效分析[J]. 介入放射学杂志, 2017, 26:531- 534.
[15] 李旭敏,郭 黔,陈 非,等. 生物微球联合碘油经肝动脉栓塞化疗治疗原发性肝癌临床观察[J]. 健康必读, 2018:2.
[16] 王兴东,张志勇,李正果,等. 栓塞微球联合碘化油在原发性肝癌TACE中的疗效观察[J]. 甘肃医药, 2019, 38:323- 325.
[17] 赵 蔚,代 福,冯国安. 中晚期肝癌患者采用Callispheres载药微球经肝动脉化疗栓塞治疗的有效性[J]. 系统医学, 2020, 5:109- 111.
[18] Vogl TJ,Langenbach MC,Hammerstingl R,et al. Evaluation of two different transarterial chemoembolization protocols using lipiodol and degradable starch microspheres in therapy of hepatocellular carcinoma: a prospective trial[J]. Hepatol Int, 2021, 15: 685- 694.
[19] 曾晓华,冯敢生,王颂章,等. 白细胞介素2葡聚糖微球并碘油栓塞治疗肝癌的动物实验[J]. 介入放射学杂志, 2006, 15:93- 96.
[20] 黄洁夫,李绍强,梁力建. 肝动脉化疗栓塞在原发性肝癌治疗中的地位和作用[J]. 中华肝胆外科杂志, 2000, 6:3- 6.
[21] 张 申,张 磊,仲斌演,等. “TACE抵抗/失败”——需要全面认识[J]. 介入放射学杂志, 2020, 29:743- 747.
[22] Zuo M, Huang J. The history of interventional therapy for liver cancer in China[J]. J Interv Med, 2018, 1: 70- 76.

相似文献/References:

[1]程洁敏,王建华.喜树碱微球化疗栓塞治疗原发性肝癌10例报告[J].介入放射学杂志,1993,(01):47.
[2]季博青,黄金华,尚克中,等.微球栓塞髂内动脉治疗晚期盆腔恶性肿瘤[J].介入放射学杂志,1993,(01):22.
[3]曾晓华,冯敢生,王颂章,等.白细胞介素2葡聚糖微球并碘油栓塞治疗肝癌的动物实验[J].介入放射学杂志,2006,(02):93.
 ZENG Xiao-hua,WANG Song-zhang,JIN De-qin.Experimental treatment of the transplanted hepatoma in rabbit by hepatic arterial embolization using interleukin-2 dextran microsphere and iodized oil[J].journal interventional radiology,2006,(03):93.
[4]李琦,范忠泽,孙珏,等.去甲斑蝥素微球对兔肝动脉栓塞作用的研究[J].介入放射学杂志,2006,(06):360.
 LI Qi,FAN Zhong-ze,SUN Jue,et al.Effect of norcatharidin microspheres on embolization of hepatic artery in rabbits[J].journal interventional radiology,2006,(03):360.
[5]陈红宇,李琦,陈庆华,等.丹参酮ⅡA-聚乳酸/羟基乙酸微球对兔肝动脉栓塞作用的研究[J].介入放射学杂志,2010,(12):977.
 CHEN Hong-yu,LI Qi,CHEN Qing-hua,et al.The embolization effect of tanshinoneⅡA-polylactic acid/glycolic acid microspheres on the hepatic artery in experimental rabbits[J].journal interventional radiology,2010,(03):977.
[6]李晓峰,钱国军,张 磊,等. 微波高功率条件下消融原发性肝癌的初步研究[J].介入放射学杂志,2011,(12):974.
 LI Xiao-feng,QIAN Guo-jun,ZHANG Lei,et al.Microwave ablation with high output power for the treatment of hepatocellular carcinoma: a preliminary study[J].journal interventional radiology,2011,(03):974.
[7]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良RECIST标准更可靠[J].介入放射学杂志,2012,(03):177.
 . Therapeutic evaluation criterion of inoperable hepatocellular carcinomas: modified RECIST as a more reliable standard[J].journal interventional radiology,2012,(03):177.
[8]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
 ,,et al.The factors related to the formation of arterioportal shunting in patients with hepatocellular carcinomas [J].journal interventional radiology,2012,(03):206.
[9]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
 .The transformation pattern of serum аfetoprotein after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: its clinical significance [J].journal interventional radiology,2012,(03):333.
[10]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ;[J].介入放射学杂志,2012,(06):469.
 SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(03):469.

备注/Memo

备注/Memo:
(收稿日期:2022- 01- 25)
(本文编辑:新 宇)
更新日期/Last Update: 2023-03-28